Immune Risk Assessment
Experts who help you generate critical information on immune drug safety in the pre-clinical phase that could be essential in the success of the drug.
We bring unique in vitro tissue damage assays combined with immune functional assays. These customised immune assays help assess the immune risk like adverse immune response and immunogenicity induced by or associated with a drug.
Move toward translational research and start predicting Immune Risk
Acquiring critical information on the drug immunogenic property before clinical trials could be pivotal in avoiding patient risks and attrition due to costly drug failure. We bring a comprehensive meaning to drug immunogenicity and an innovative method of assessing immunological risk. We emphasise the analysis of drug-induced tissue damage. The immune response generated by such damage could lead to serious drug adversity. We use an in vitro human platform analysing biomarkers of immune risk and response (adaptive) and help predict drug immunogenicity.
Drug Immunogenicity
Drug immunogenicity means a lot more than ‘ADA’ (drug antigenicity) and ‘cytokine storm’. We provide assays related to cytokine storm such as CRA, but also important tissue-based studies that are important for other immunogenic responses such as cytotoxicity and immunotoxicity.
Tissue Damage & Immune Response Studies
At Immundnz, we have a wide range of models based on cell lines and/or primary cells that can stage the interaction between tissues and cells and test the effect of drugs on tissue damage.
Learn how Immundnz guides Immune Risk Assessment
Vaccines against SARS-CoV-2 corona virus can be designed using the S protein, and also the entirety containing the M protein. The virus is suspected to cause cytokine storm in some patients. What is the possibility of any of these free proteins released from the vaccine to cause a serious adverse immune response?
How do you benefit from Immune Risk Assessment?
Prediction of immune-mediated adverse drug reaction can help you avoind risk in clinical phase and to better make the translation from pre-clinical studies to humans
- Reduction of the number of animal tests
- A more robust and comprehensive immunologic profile: improved safety and risk prediction, thus reducing human health hazard risk
- You can terminate drug development before costly advanced stages of drug development
- Potential to improve drugs, generate blocking agents against immune effectors and make non-viable drugs accessible to patients
- Meeting changes to regulatory requirements on immunologic safety
Looking For A Tailor-Made Solution?
Leave us a message and we will be in touch shortly. We look forward to meeting you!
